Portland, OR – September 29, 2017 – MolecularMD, a provider of molecular and tissuebased clinical trial assays and diagnostics for oncology based drug development programs,
Dr. Keith J. Kaplan | July 31, 2017 | Source: Indica Labs Indica Labs announced today that Douglas Bowman has been appointed Vice President, Pharma
Indica Labs Appoints a Vice President, Pharma Services Read More »
Corrales, NM – April 24th 2017 – Indica Labs proudly announces its breakthrough HALO® Deep Learning technology excelled in the CameLyon17 diagnostic image analysis competition.
HALO® Deep Learning Technology Awarded for Automated Breast Cancer Metastasis Staging Read More »
Tokyo, 9 January, 2017 – Indica Labs expanded its international presence again this month with the establishment of a new office in Tokyo, Japan and
Indica Labs, in conjunction with Global Engage Digital Pathology Congress 2017, formally invites you to take in a unique view of the Chicago Skyline while
Indica Labs invites you to Cruise Chicago with us Read More »
Corrales, NM – 2 November, 2016 – Indica Labs, a leading provider of software for quantitative evaluation of digital pathology images, is pleased to announce
You’re Invited Indica Labs would like to formally invite you to our European Quantitative Pathology Meeting in London which will be held on Wednesday 30th November from 12:00-5
You’re Invited to our European Quantitative Pathology Meeting Read More »
Indica Labs’ Sales Application Scientist Adam Smith will be presenting on the STRATA Platform July 14th from 11:45-12:15 at the 2nd Digital Pathology Congress in
Join Indica Labs at the 2nd Digital Pathology Congress in Philadelphia Read More »
Indica Labs would like to formally invite you to the Inaugural East Coast HALOTM User Group Meeting which will be held on 11th February, 2016
Inaugural East Coast HALO User Group to be held in Cambridge, MA on February 11, 2016 Read More »
Discoveries from the field: Expediting drug developments and clinical trials with digital pathology and HALO image analysis Alex Klimowicz, PhD, Principal Scientist, Boehringer Ingelheim Pharmaceuticals
